CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer. She is a strategic business leader with deep experience managing finance and planning across the full range of biopharmaceutical R&D, commercial and business operations, including leadership roles at Arrakis Therapeutics, Agios Pharmaceuticals, and Biogen. Ms. Radcliffe joins Affinivax at a pivotal time as the company evolves its vaccine pipeline and expands its operations.
“We are delighted to welcome Liz to our leadership team, and her extensive financial and planning experience will be a strong asset for Affinivax as we advance our vaccine pipeline and grow our business,” said Steven Brugger, Chief Executive Officer of Affinivax. “Liz is a seasoned and passionate leader, with deep knowledge of drug development and commercialization and experience managing through growth. I look forward to her contributions in building our financial and operational competences as we further advance our clinical portfolio of vaccines.”
“I am excited to apply my experience to driving the next stage of Affinivax’ journey as a leading vaccine innovator,” said Ms. Radcliffe. “I see tremendous potential for the MAPS platform to bring innovation to the vaccine field and have an important impact on human health. I look forward to helping realize that promise as a member of the Affinivax executive team.
Elizabeth Radcliffe brings over 20 years of experience, with progressive financial leadership roles across the biopharmaceutical value chain at both large and small organizations, including contribution to six product launches. She most recently served as Vice President, Finance and Strategy and Treasurer at Arrakis Therapeutics. Prior to Arrakis, Ms. Radcliffe was Vice President, Financial Planning & Analysis at Agios Pharmaceuticals and spent over 10 years at Biogen, culminating in the role of Senior Director, Head of R&D Finance, where she led financial planning and accounting for Biogen’s worldwide R&D and Medical Affairs functions. Her prior leadership roles at Biogen included head of U.S. revenue planning for Biogen’s Multiple Sclerosis and Hemophilia franchises, Head of Portfolio Management, and Director of Corporate FP&A, with earlier experience supporting Business Development and Technical Operations. Earlier in her career, Ms. Radcliffe held consulting positions at The Parthenon Group and Excelon Corporation. She holds a B.S. in chemistry from Yale University, a Master’s degree in organic chemistry from Harvard University, and an M.B.A. from the MIT Sloan School of Management.
About Affinivax, Inc.
Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ platform technology, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children’s Hospital. For more information, visit www.affinivax.com.